Background: Prader-Willi syndrome (PWS) is a genetic disorder due to loss of expression of paternally transcribed genes of the imprinted region of chromosome 15q11-13. PWS is characterized by peculiar signs and symptoms and many endocrine abnormalities have been described
Introduction
Prader-Willi syndrome (PWS) is the first genetic syndrome recognized to be related to imprinting region alterations and it represents a complex multisystem disorder characterized by neurological, behavioral, physical and endocrine dysfunctions [1] .
PWS is due to the loss of expression of paternally transcribed genes in the region 15q11-13 [2] . Approximately 60-75% of affected subjects have a microdeletion of the paternal chromosome (del15) [2, 3] , 25-30% of cases present a maternal uniparental disomy (UPD) involving the same region, while few cases (1-2%) result from a mutation involving the imprinting center or other chromosomal rearrangement in chromosome 15 [4] .
The incidence of PWS ranges from 1:15,000 to 1:30,000 live newborns and it is possible that many affected subjects remain undiagnosed [5] . PWS affects males and females indistinctly and is clinically characterized by hypotonia and feeding problems during the neonatal period, hyperphagia and rapid weight gain after the first year of life, mental retardation, behavioral problems and hypogenitalism in the following years [6, 7] . Hypothalamic and pituitary dysfunctions are distinguishing features of PWS. In fact, neuroradiological alterations, such as anterior pituitary hypoplasia and complete absence of the posterior pituitary bright spot, have been demonstrated in 67-74% [8, 9] of patients with PWS. These findings well fit with the presence in PWS patients of both alteration in growth hormone (GH) secretion and hypogonadotropic hypogenitalism. These endocrine dysfunctions were greatly investigated in literature, while few studies evaluated the thyroid function in patients with PWS. A possible relationship between the syndrome and a high incidence of central hypothyroidism has been hypothesized [10] , but some authors concluded that the prevalence of hypothyroidism was not different between PWS patients and the general population [11, 12] .
The aim of our study was to analyze thyroid function data in a large study group of PWS patients in order to define the prevalence and the type of thyroid dysfunction related to this syndrome.
Subjects and methods
In this cross-sectional study we enrolled PWS patients with a genetically confirmed diagnosis who were regularly followed in 14 Collected anthropometric and laboratory data were those recorded during the nearest visit before the recruitment into the study.
To evaluate the prevalence of congenital hypothyroidism we used data from neonatal screenings. In fact, as prescribed in our country, all subjects were submitted to a neonatal screening with a combined approach, determining at the same time both TSH and thyroxine in dried blood spots collected between 48 and 72 h after birth [13] . The screening test was routinely repeated on the same blood spot in double every time TSH > 10 U/L (threshold level for retest). When the values again exceed the cut-off level of 10 U/L, the newborn was referred to a functional thyroid assessment in serum.
Out of neonatal period, an automated chemiluminescent immunoassay was used to measure fT4 (Access; Beckman Coulter, Fullerton, CA, USA; intra-assay coefficient of variation [CV], <4.5%; interassay CV, <8.1%), TSH (Access HYPERsensitive hTSH assay; Beckman Coulter; intra-assay CV, <5.9%; interassay CV, <8.9%) and fT3 (Centaur, Siemens Healthcare Diagnostics, Tarrytown, NY, USA; intra-assay CV, <3.1%; total imprecision, <4.1%).
Subjects' thyroid function was classified as: -euthyroidism (EuT): normal fT4 and TSH ≤ 5 μIU/mL -congenital hypothyroidism (C-HT) -hypothyroidism (HT -high TSH and low fT4): low fT4 and TSH ≥ 10 μIU/mL -central hypothyroidism (CE-H -low/normal TSH and low fT4): low fT4 and TSH ≤ 5 μIU/mL -subclinical hypothyroidism (SH -high TSH and normal fT4): normal fT4 and TSH > 5 μIU/mL -hyperthyroidism (HyperT -low TSH and high fT4)
Ethical approval: written informed consent was provided by parents of PWS patients while assent was obtained by children and adolescents when appropriate and before data collection. The research related to human use complied with all the relevant national regulations, institutional policies and was in accordance with the tenets of the Helsinki Declaration, and has been approved by the authors' institutional review board or equivalent committee. All results are reported as the mean ± standard deviation (SD) and median. Data were checked for normal distribution using the Kolmogorov-Smirnov test and nonparametric statistical analysis (STATISTICA™ software, StatSoft Inc., Tulsa, OK, USA) was performed. Between-group comparisons were evaluated using the Mann-Whitney's U-test and Pearson's chi-square (χ 2 ) for two-way observed frequencies. For each test, statistical significance was considered for p < 0.05.
Results
Three hundred and thirty-nine PWS patients (233 males, 68.7%), ages 11.1 ± 11.6 years (range 0.22-50.0 years) were recruited in the study: 96 were adults (28.3%; >18 years), 18 were adolescents (5.3%; 14-18 year) and 225 were children (66.4%; 0-14 years). Considering the small number of adolescents, data from children and adolescents were analyzed as a single group (243 patients; 71.7%; 0-18 years).
All PWS patients had the genetically confirmed diagnosis. Deletion (Del) was found in 192 out of 339 patients (56.6%), UPD in 116 (34.2%). In 27 subjects (8%) an altered methylation profile was founded without further genetic exams and in four patients (1.2%) translocations of Cr.15q11-13 were recognized.
Anthropometric data
Auxological characteristics of the whole study population are reported in Table 1 .
Median Ht SDS was −1.97 and median BMI SDS was 1.85. Analyzing data according to genetic features, we demonstrated that BMI SDS was significantly higher in subjects with Del respect to UPD (1.84 ± 2.32 vs. 0.76 ± 2.61, respectively; p < 0.05) and other genetic findings.
We demonstrated that children and adolescents, with respect to adults, had significantly higher Ht SDS (−1.49 ± 1.28 vs. −3.92 ± 1.31, respectively; p < 0.0001) and both had significantly lower BMI (20.4 ± 8.38 vs. 42.7 ± 11.7 kg/m 2 , respectively; p < 0.0001) and BMI SDS (0.67 ± 2.41 vs. 3.37 ± 1.28, respectively; p < 0.0001).
Analyzing data according to gender, in adults Ht SDS was significantly different between males and females (−4.09 ± 1.17 vs. −2.58 ± 1.55, respectively; p = 0.004), while no difference in anthropometric data was shown in children and adolescents according to gender.
Thyroid function
In our study, 293 subjects had normal thyroid function (EuT) while 46 out of 339 patients (13.6%; 27 males) had abnormal thyroid function.
Mean TSH, fT4 and fT3 were in the normal range. fT4 levels were significantly lower in children and adolescents than in adults, as reported in Table 2 .
The most frequent thyroid dysfunction was represented by CE-H resulting in 6.8% of the whole population (n. 23). Specifically, 10 out of 23 CE-H (43.5%) were found in recruited PWS children younger than 1 year and none was in substitutive therapy with L-thyroxine. Other alterations of thyroid function were SH in 3.8% (n. 13), HT in 1.8% (n. 6), and C-HT in 1.2% (n. 4). None had hyperthyroidism.
The prevalence data of each type of abnormal thyroid function were not different between children, adolescent and adults (Pearson's χ 2 = 6.34; p = 0.175; Table 3 ). At the time of the study recruitment, all patients with C-HT, five out 23 patients with CE-H and two out six with HT were in substitutive therapy with L-thyroxine. Data are reported as mean ± SD (median) and were compared between the adult group and the children and adolescents one. Ht, height; SDS, standard deviation score; Wt, weight; BMI, body mass index; PWS, Prader-Willi syndrome. Data are reported as mean ± SD (median) and were compared between the adult group and the children and adolescents one. TSH, thyroid-stimulating hormone; fT3, free triiodothyronine 3; fT4, free thyroxine 4; PWS, Prader-Willi syndrome.
Analyzing the prevalence of abnormal thyroid function according to genetic PWS diagnosis, we did not show any statistically significant data (Pearson's χ 2 = 9.76; p = 0.636; Table 4 ).
At enrolment 66 out of 243 children and adolescents (19.5%) were treated with rhGH (mean dose 0.168 ± 0.061 mg/kg/week), while 37 patients (10.9%) stopped the therapy before the recruitment.
No differences were shown about thyroid function between rhGH treated and the not treated subjects.
Discussion
For many years the thyroid function in subjects with PWS was not really well investigated because it was generally considered to be normal or minimally altered.
In recent years, however, a few studies have examined the thyroid function showing different results [8, [10] [11] [12] [14] [15] [16] [17] . In fact, the prevalence of abnormal thyroid function in these studies largely ranged from 2 to 32% in a total number of about 300 patients (0.25-44 years). Data are presented as number of patients (n) and percentage according to the genetic mutation group (row) and the thyroid function group (column). UPD, uniparental disomy; EuT, euthyroidism; CE-H, central hypothyroidism; SH, subclinical hypothyroidism; HT, hypothyroidism; C-HT, congenital hypothyroidism; PWS, Prader-Willi syndrome. In the present study we examined a population of children, adolescents and adults with PWS larger than the total number of patients enrolled in previous published studies.
Our study population reflects well the clinical findings of the PWS. Anthropometric data have confirmed typical features of the syndrome with an important increase of BMI from childhood to adulthood. It is noticeable that our Italian centers maintained the mean BMI SDS of children and adolescents within the normal range.
Also, different types of genetic alteration demonstrated in our patients were substantially comparable with the literature data [2, 18] with a high prevalence of Del (57%) followed by UPD (34%).
In our large population study, we demonstrated a relatively high prevalence of abnormal thyroid functions, presented by 46 out of 339 patients (13.6%) with a high frequency in males. Our prevalence is clearly higher than that previously reported by Butler et al. [11] . These authors, examining 47 patients with PWS, found a similar frequency of hypothyroidism compared to the general population (2 vs. 2.1%, respectively) and ruled out the existence of an alteration of hypothalamic-pituitary-thyroid axis in PWS subjects.
Sharkia et al. [12] reported that thyroid function was normal at newborn screening. Moreover, in older children, the authors revealed a hypothyroidism only in one out of 21 studied subjects.
Festen et al. [16] evaluated the thyroid function in children with PWS and showed that five children (6.3%) had a genuine hypothyroidism. This prevalence of hypothyroidism is substantially in line with our data.
On the other hand, the prevalence of all abnormal thyroid functions we found in our patients with PWS (13.6%) is largely lower than that showed by Diene et al. [17] . These authors evaluated the French database of PWS and showed that 31/127 (24.4%) were affected by hypothyroidism. In this latter study, however, hypothyroidism diagnosis was done according to fT4 and/or fT3 levels below normal values without taking into consideration the TSH value. This aspect implies that in this study it is not possible to distinguish the different types of hypothyroidism. Moreover, the authors based their diagnoses of hypothyroidism on the pediatric endocrinologists' own reference ranges rather than on laboratory values. For this reason, the estimated prevalence could be not considered totally exact.
Considering the large number of our studied patients, we believe that our data could well represent a real prevalence. An interesting finding of our study is the relative high number of patients with the C-HT (n. 4). To the best of our knowledge, to date only two cases of C-HT have been reported in the literature [19, 20] and one of them is also included in our population. Interestingly both cases were characterized by an ectopic thyroid gland. The other three patients had thyroid agenesis. It is conceivable that the relatively high number of our patients with C-HT could result from the mandatory thyroid neonatal screening in Italy.
The largest proportion of abnormal thyroid function in our population was represented by the CE-H (23/42) which is probably due to the alteration of the hypothalamic-pituitary-thyroid axis. Even if our results are not supported by published studies [11, 12, 21] , a central alteration was well documented in other ones. The highest prevalence of CE-H was reported by Miller et al. [8] with 19% of cases in a group of 27 PWS subjects (mean age 12.6 years, 0.25-39). Vaiani et al. [10] studied 18 infants with PWS (age 0.16-2 years) and showed low levels of thyroid hormones with normal TSH in 13 out of 18 patients. These authors concluded that in PWS patients there is a high incidence of transient or definitive hypothalamic-pituitary-thyroid axis dysfunction. Also in our study the infants were particularly concerned by CE-H because 10/19 (52.6%) of the patients with CE-H were younger than 1 year while another four cases were found in children between 1 and 2 years of age.
Our data suggest that in children with PWS such hypothalamic-pituitary-thyroid axis dysfunction could be considered a common feature, that thyroid function should be already investigated within the first year of life and a regular follow-up should be performed annually.
In our patients with PWS the prevalence of both HT and SH was similar to that of the general population [22] .
Finally, in our patients, GH therapy does not seem to cause an increase of the prevalence of different forms of hypothyroidism. The relationship between GH secretion and thyroid function, as well as the effects of administration of rhGH therapy on serum thyroid hormone levels, were evaluated in several published studies [20, 21, 23, 24] . During therapy with rhGH, a transient decrease in fT4 levels associated with an increased conversion to fT3 and a decreased in TSH concentration, were shown. However, hormone levels remained always within the normal range.
Our study has some limitations. First of all, it is a transversal study. Certainly, a longitudinal study would allow more information on the natural history of thyroid function, on the time of appearance of a thyroid dysfunction, mainly on central hypothyroidism and on its eventual transitory character. However, our data on a large group of PWS patients showing that 43.5% of CE-H forms are present in children younger than 1 year allow us to suggest an assessment of thyroid function already in the first year of life. Moreover, in our population study it was not possible to collect all data on thyroid autoantibodies and thyroid ultrasounds, so it is not possible for us to clearly define the nature of hypothyroidism forms we found.
Conclusions
Hypothalamic-hypophysis-thyroid axis dysfunction appears to be a common feature in PWS patients both in children and adults. The most significant and innovative data of our study are both the relevant frequency of C-HT in patients with PWS and the high percentage of CE-H, confirming the well-known presence of hypothalamicpituitary dysfunction in PWS.
As the relative clinical presentation of hypothyroidism, whether central or peripheral, can be mistaken for some symptoms of the syndrome (i.e. muscular hypotonia, lethargy and poor sucking often resulting in failure to thrive), we suggest to regularly monitor, immediately after PWS diagnosis and at least annually at follow-up, thyroid function, so that any abnormal thyroid function does not remain unrecognized.
Pediatricians should always remember the association being evaluated and followed-up by a patient with PWS to recognize and treat any dysfunctions that may worsen the outcome, particularly in the first year of life.
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